Navigation Links
BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors

BURLINGAME, Calif., Feb. 5 /PRNewswire/ -- BioSeek, Inc. today announced that Roy A. Whitfield has been elected executive chairman of the Company's board of directors. Mr. Whitfield had joined BioSeek's board of directors and served as a business advisor to the Company since November, 2005.

"Roy's management experience and expertise in drug discovery and business development have been extraordinarily valuable to BioSeek thus far. We look forward to his continued leadership and guidance as executive chairman as we advance our internal drug discovery and development efforts and continue to secure corporate partnerships that capitalize upon our BioMAP(R) screening systems platform," said Michael C. Venuti, Ph.D., CEO of BioSeek.

Roy Whitfield has over 20 years of management and governance experience in the biotechnology industry. Most recently, Roy served as CEO and Chairman of Incyte Corporation, a genomics company he co-founded in 1991. Incyte pioneered the commercialization of high throughput and information technology in pharmaceutical and medical research. At Incyte, Roy executed the first genomics initial public offering (IPO) and later raised over $700 million in financing. In 1997, he was named Northern California "Entrepreneur of the Year" for Life Sciences. Roy also serves on the boards of directors of Incyte Corporation, Nektar Therapeutics, Illumina and several private companies, and in the past served on the boards of Aurora Biosciences and the Biotechnology Industry Organization (BIO). Roy received a B.A. degree from Oxford University and an M.B.A. from Stanford University.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to

BioSeek Contacts:

BioSeek, Inc.

Michael Venuti, Ph.D.


Tel: 650.552.0754

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 781.235.3060

SOURCE BioSeek, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProCure Selects IMPAC as Provider of Oncology Information Systems
2. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
3. GSA Selects Cascades Technologies, Inc. (CTi) to Support
4. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
5. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
6. GeneSeek Selects the British Midlands as Base for New UK/European Operations
7. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
10. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
11. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):